NextRNA Therapeutics, Inc. is a MA-based newly founded biotechnology company committed to leading the next revolution of RNA-directed therapeutics. Based on the foundational work of Carl Novina at Dana-Farber Cancer Institute, NextRNA has established a proprietary target and drug discovery engine that enables us to systematically identify disease-relevant long non-coding RNAs and their interacting proteins, and develop selective small molecules to drug RNA-protein interactions.
The company is currently advancing two small molecule therapeutic programs in oncology and immunology.
NextRNA has assembled a highly experienced and competent team of industry leaders, biology and chemistry experts, and drug developers, all driven by a common passion for working together and having an impact on science and patients.
The company is currently advancing two small molecule therapeutic programs in oncology and immunology.
NextRNA has assembled a highly experienced and competent team of industry leaders, biology and chemistry experts, and drug developers, all driven by a common passion for working together and having an impact on science and patients.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $46.8M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | Lightchain... | lightchain... |
| - | Cobro Vent... | cobroventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.03.2022 | Series A | $46.8M | Lightchain... |
Mentions in press and media 1
| Date | Title | Description |
| 01.03.2022 | NextRNA Therapeutics Raises $56M in Seed and Series A Funding | NextRNA Therapeutics, a Cambridge, Mass.-based biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, launched with $9.3m in seed financing and a $46.8m in Series A funding. The round was le... |